The goal of this activity is for learners to be better able to apply safety and efficacy data on Janus kinase ( JAK) inhibitors and stratify patients based on risk when developing.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001750
- Start Date: 2024-10-15 05:00:00
- End Date: 2024-10-15 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: AbbVie (Any division) - Amount: 71900.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Rheumatology
Subscribe
Login
0 Comments
Oldest